Skip to main navigation
LinkedIn Twitter
  • Investors
  • Careers
Outlook Therapeutics, Inc. Logo
  • About
    • Overview
    • Senior Leadership
    • Board of Directors
  • Pipeline
    • ONS-5010 / LYTENAVA™ OVERVIEW
    • ONS-5010 CLINICAL PROGRESS
    • UNMET PATIENT NEEDS
    • REPACKAGED IV BEVACIZUMAB
    • NEW OPHTHALMIC ANTI-VEGF
    • POTENTIAL FIRST-LINE THERAPY
  • News
  • Contact

SEC Filings

Home / Investors / SEC Filings / 8-K

SEC Filing Details

Document Details

Form
8-K
Filing Date
Mar 25, 2022
Document Date
Mar 21, 2022
Form Description
Report of unscheduled material events or corporate event
Filing Group
Current Reports
Company
Outlook Therapeutics, Inc.
Issuer
OUTLOOK THERAPEUTICS, INC.

Filing Formats

View HTML
Download PDF
Download DOC
Download XLS

XBRL

XBRL Viewer
EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA
EX-101.DEF - XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
EX-101.LAB - XBRL TAXONOMY EXTENSION LABEL LINKBASE
EX-101.PRE - XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
XML - XBRL INSTANCE DOCUMENT
  • Investor Overview
  • Stock Information
    • Stock Quote & Chart
    • Historical Price Lookup
    • Investment Calculator
    • Other Shareholder Information
  • Financial Information
    • SEC Filings
  • Analyst Coverage
  • News & Events
    • Press Releases
    • Events
    • In the News
    • Presentations
  • Corporate Governance
    • Governance Highlights
    • Senior Leadership
    • Board of Directors
    • Committee Composition
  • Information Request
  • Print Page Print Page
  • Email Page Email Page
  • RSS Feeds RSS Feeds
  • Email Alerts Email Alerts
  • Contact IR Contact IR
© 2022 Outlook Therapeutics, Inc.
Privacy Policy | Disclaimer